Is It Time To Reassess Caris Life Sciences (CAI) After Its Recent Share Price Swings

• If you are wondering whether Caris Life Sciences at around US$20.83 offers good value, the key is understanding how the current price lines up against its fundamentals.
• The stock has recently been active, with a 3.2% return over the last 7 days and 13.1% over the last 30 days, but a 22.8% decline year to date, which can change how investors think about both opportunity and risk.
• Recent news coverage has focused on Caris Life Sciences as part of the broader interest in healthcare and biotech names. This highlights how sentiment can swing quickly when attention shifts across the sector and provides useful context for the recent share price moves and why the company is back on some investors' watchlists.
• On Simply Wall St's valuation checks, Caris Life Sciences scores 4 out of 6. This sets the stage for comparing different valuation approaches next, along with a broader way of thinking about what this score really means for you later in the article.

Caris Life Sciences delivered 0.0% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Approach 1: Caris Life Sciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return. The aim is to work out what those future cash streams are worth in today’s dollars.

For Caris Life Sciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow sits at about $58.2 million. Analyst estimates and subsequent extrapolations point to free cash flow of $416.15 million by 2030, with a path of projected cash flows between 2026 and 2035 that are discounted back to the present.

Putting all of those discounted cash flows together gives an estimated intrinsic value of US$38.54 per share, compared with the current share price of around US$20.83. On this basis, the DCF output suggests the stock trades at a 45.9% discount to the model’s estimate of fair value, which indicates it may be undervalued on these cash flow assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Caris Life Sciences is undervalued by 45.9%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Caris Life Sciences.

Approach 2: Caris Life Sciences Price vs Sales

Approach 2: Caris Life Sciences Price vs Sales

For companies where profits are not the main focus yet, the P/S ratio is often more useful than P/E or P/B, because it ties the share price directly to the revenue being generated, regardless of current earnings.

Growth expectations and risk still matter here, because investors are usually willing to pay a higher P/S multiple when they expect stronger future growth or see lower business risk, and a lower multiple when growth is uncertain or risks are higher.

Caris Life Sciences trades on a P/S ratio of 7.25x, compared with the Biotechs industry average of 11.53x and a peer average of 11.72x. Simply Wall St’s Fair Ratio for Caris Life Sciences is 6.18x, which is its proprietary estimate of what a reasonable P/S multiple could be for this company based on factors like earnings growth, industry, profit margins, market cap and identified risks.

This Fair Ratio can be more informative than a basic peer or industry comparison, because it adjusts for the specific profile of Caris Life Sciences rather than assuming all companies deserve similar multiples. With the actual P/S at 7.25x versus a Fair Ratio of 6.18x, the shares screen as somewhat expensive on this metric.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Caris Life Sciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and that is through Narratives. These let you attach a clear story and set of assumptions to the numbers by linking your view of Caris Life Sciences, such as whether it should be worth US$26.23, US$38.11 or US$45.00 per share, to specific forecasts for future revenue, earnings and margins. You can then compare that Fair Value with today’s price inside Simply Wall St’s Community page, where Narratives are easy to use, update automatically as new earnings or news arrive, and help you decide whether the current price looks attractive or stretched based on the story you believe most.

Do you think there's more to the story for Caris Life Sciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com